An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
AlloVir to Present at the BofA Securities 2023 Health Care Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
WALTHAM, Mass.--(BUSINESS WIRE)--
AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T cell immunotherapy company, announced today that Diana Brainard, M.D., Chief Executive Officer, will participate in a fireside chat at the BofA Securities 2023 Health Care Conference in Las Vegas, NV on Tuesday, May 9, 2023, at 8:40 a.m. PDT.
A live webcast and archived replay of the presentation will be available on the Investors & Press section of the AlloVir website at https://ir.allovir.com.
About AlloVir
AlloVir is a leading late clinical-stage cell therapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. The company’s innovative and proprietary technology platforms leverage off-the-shelf, allogeneic, single- and multi-virus-specific T cells for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. AlloVir’s technology and manufacturing process enable the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. The company is advancing multiple mid- and late-stage clinical trials across its product portfolio. For more information visit www.allovir.com or follow us on Twitter or LinkedIn.
allovir, inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific t cell (vst) therapies to prevent and treat devastating viral-associated diseases. the company's lead product is viralym-m, an allogeneic, off-the-shelf vst therapy, to treat bk virus, cytomegalovirus, adenovirus, epstein-barr virus, and human herpesvirus 6. its preclinical and clinical development product candidates include alvr106 for respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; alvr109 to treat sars-cov-2 and covid-19; alvr107 for treating hepatitis b; and alvr108 to treat human herpesvirus-8, including kaposi's sarcoma, primary effusion lymphoma, and multicentric castleman's diseases. the company was formerly known as viracyte, inc. and changed its name to allovir, inc. in may 2019. allovir, inc. was founded in 2013 and is based in cambridge, massachusetts.
